MedTrace Logo

Dry Eye Disease Study With Brimonidine

NCT03418727 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-07-06

Study results available
· View outcomes & findings →

Summary

To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).

Conditions

  • Dry Eye

Interventions

DRUG

Brimonidine

Two products delivered in sequence twice daily.

DRUG

Brimonidine Mono Therapy

Brimonidine given twice daily along with placebo drops

DRUG

sodium carboxymethylcellulose

Placebo given twice daily.

DRUG

Corticosteroid Eye Drop

Eye drop to be administered after Brimonidine in treatment arm 1

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-06
Primary Completion
2018-03-29
Completion
2018-03-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418727 on ClinicalTrials.gov